CLINICAL RESEARCH: HEART FAILURE/TRANSPLANTATION
Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction
Paul A. Heidenreich, MD, MS* ,*,
Matthew A. Gubens, MS,
Gregg C. Fonarow, MD ,
Marvin A. Konstam, MD ,
Lynne W. Stevenson, MD|| and
Paul G. Shekelle, MD, PhD¶
* VA Palo Alto Health Care System, Palo Alto, California, USA
Stanford University School of Medicine, Stanford, California, USA
University of California at Los Angeles School of Medicine, Los Angeles, California, USA
Tufts-New England Medical Center, Boston, Massachusetts, USA
|| Brigham and Women's Hospital, Boston, Massachusetts, USA
¶ Greater Los Angeles VA Healthcare System, Los Angeles, California, USA
Manuscript received September 12, 2003;
accepted October 15, 2003.
* Reprint requests and correspondence: Dr. Paul A. Heidenreich, 111C Cardiology, Palo Alto VAMC, 3801 Miranda Avenue, Palo Alto, California 94034, USA.
heiden{at}stanford.edu
OBJECTIVES: This study was designed to evaluate the cost-effectiveness of screening patients with a B-type natriuretic peptide (BNP) blood test to identify those with depressed left ventricular systolic function.
BACKGROUND: Asymptomatic patients with depressed ejection fraction (EF) may have less progression to heart failure if they can be identified and treated.
METHODS: We used a decision model to estimate economic and health outcomes for different screening strategies using BNP and echocardiography to detect left ventricular EF <40% for men and women age 60 years. We used published data from community cohorts (gender-specific BNP test characteristics, prevalence of depressed EF) and randomized trials (benefit from treatment).
RESULTS: Screening 1,000 asymptomatic patients with BNP followed by echocardiography in those with an abnormal test increased the lifetime cost of care ($176,000 for men, $101,000 for women) and improved outcome (7.9 quality-adjusted life years [QALYs] for men, 1.3 QALYs for women), resulting in a cost per QALY of $22,300 for men and $77,700 for women. For populations with a prevalence of depressed EF of at least 1%, screening with BNP followed by echocardiography increased outcome at a cost <$50,000 per QALY gained. Screening would not be attractive if a diagnosis of left ventricular dysfunction led to significant decreases in quality of life or income.
CONCLUSIONS: Screening populations with a 1% prevalence of reduced EF (men at age 60 years) with BNP followed by echocardiography should provide a health benefit at a cost that is comparable to or less than other accepted health interventions.
|
Abbreviations and Acronyms
| | ACE | = angiotensin-converting enzyme | | BNP | = B-type natriuretic peptide | | ECG | = electrocardiogram | | EF | = ejection fraction | | HF | = heart failure | | LV | = left ventricular | | QALY | = quality-adjusted life year | | SOLVD | = Studies Of Left Ventricular Dysfunction |
|
This article has been cited by other articles:
|
|
|
|
 
S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al.
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation
J. Am. Coll. Cardiol.,
April 14, 2009;
53(15):
e1 - e90.
[Full Text]
[PDF]
|
|
|
|
|
|
|
2005 WRITING COMMITTEE MEMBERS, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, et al.
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation
Circulation,
April 14, 2009;
119(14):
e391 - e479.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Troughton and A. M. Richards
B-type natriuretic peptides and echocardiographic measures of cardiac structure and function.
J. Am. Coll. Cardiol. Img.,
February 1, 2009;
2(2):
216 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Maisel, C. Mueller, K. Adams Jr., S. D. Anker, N. Aspromonte, J. G.F. Cleland, A. Cohen-Solal, U. Dahlstrom, A. DeMaria, S. Di Somma, et al.
State of the art: Using natriuretic peptide levels in clinical practice
Eur J Heart Fail,
September 1, 2008;
10(9):
824 - 839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. D. Schocken, E. J. Benjamin, G. C. Fonarow, H. M. Krumholz, D. Levy, G. A. Mensah, J. Narula, E. S. Shor, J. B. Young, and Y. Hong
Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group
Circulation,
May 13, 2008;
117(19):
2544 - 2565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Daniels and A. S. Maisel
Natriuretic Peptides
J. Am. Coll. Cardiol.,
December 18, 2007;
50(25):
2357 - 2368.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Goode, A. L. Clark, J. A. Bristow, K. B. Sykes, and J. G.F. Cleland
Screening for left ventricular systolic dysfunction in high-risk patients in primary-care: A cost-benefit analysis
Eur J Heart Fail,
December 1, 2007;
9(12):
1186 - 1195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mogelvang, J. P. Goetze, P. Schnohr, P. Lange, P. Sogaard, J. F. Rehfeld, and J. S. Jensen
Discriminating Between Cardiac and Pulmonary Dysfunction in the General Population With Dyspnea by Plasma Pro-B-Type Natriuretic Peptide
J. Am. Coll. Cardiol.,
October 23, 2007;
50(17):
1694 - 1701.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. McDonald, C. Conlon, and M. Ledwidge
Disease management programs for heart failure: Not just for the 'sick' heart failure population
Eur J Heart Fail,
February 1, 2007;
9(2):
113 - 117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Konstam
Natriuretic Peptides and Cardiovascular Events: More Than a Stretch
JAMA,
January 10, 2007;
297(2):
212 - 214.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Goetze, R. Mogelvang, L. Maage, H. Scharling, P. Schnohr, P. Sogaard, J. F. Rehfeld, and J. S. Jensen
Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction
Eur. Heart J.,
December 2, 2006;
27(24):
3004 - 3010.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. H. Chen and J. C. Burnett Jr
Clinical application of the natriuretic peptides in heart failure
Eur. Heart J. Suppl.,
September 1, 2006;
8(suppl_E):
E18 - E25.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. R. Goldberg and M. Jessup
Stage B Heart Failure: Management of Asymptomatic Left Ventricular Systolic Dysfunction
Circulation,
June 20, 2006;
113(24):
2851 - 2860.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. McKie, R. J. Rodeheffer, A. Cataliotti, F. L. Martin, L. H. Urban, D. W. Mahoney, S. J. Jacobsen, M. M. Redfield, and J. C. Burnett Jr
Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide: Biomarkers for Mortality in a Large Community-Based Cohort Free of Heart Failure
Hypertension,
May 1, 2006;
47(5):
874 - 880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Chen, M. J. Wood, D. G. Krauser, A. L. Baggish, R. Tung, S. Anwaruddin, M. H. Picard, and J. L. Januzzi
NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy
Eur. Heart J.,
April 1, 2006;
27(7):
839 - 845.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C. Costello-Boerrigter, G. Boerrigter, M. M. Redfield, R. J. Rodeheffer, L. H. Urban, D. W. Mahoney, S. J. Jacobsen, D. M. Heublein, and J. C. Burnett Jr
Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide in the General Community: Determinants and Detection of Left Ventricular Dysfunction
J. Am. Coll. Cardiol.,
January 17, 2006;
47(2):
345 - 353.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Maisel
The Coming of Age of Natriuretic Peptides: The Emperor Does Have Clothes!
J. Am. Coll. Cardiol.,
January 3, 2006;
47(1):
61 - 64.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Developed in Collaboration With the American Colle, Endorsed by the Heart Rhythm Society, S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, et al.
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure)
J. Am. Coll. Cardiol.,
September 20, 2005;
46(6):
1116 - 1143.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Hunt, W. T. Abraham, M. H. Chin, A. M. Feldman, G. S. Francis, T. G. Ganiats, M. Jessup, M. A. Konstam, D. M. Mancini, K. Michl, et al.
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society
Circulation,
September 20, 2005;
112(12):
1825 - 1852.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. McKie and J. C. Burnett Jr
B-Type Natriuretic Peptide as a Biomarker Beyond Heart Failure: Speculations and Opportunities
Mayo Clin. Proc.,
August 1, 2005;
80(8):
1029 - 1036.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Schillinger
Cardiovascular Risk Stratification in Older Patients: Role of Brain Natriuretic Peptide, C-Reactive Protein, and Urinary Albumin Levels
JAMA,
April 6, 2005;
293(13):
1667 - 1669.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. L. Ng, I. W. Loke, J. E. Davies, S. Geeranavar, K. Khunti, M. A. Stone, D. T. Chin, and I. B. Squire
Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides
J. Am. Coll. Cardiol.,
April 5, 2005;
45(7):
1043 - 1050.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K Prasad, R. G Assomull, and D. J Pennell
Recent developments in non-invasive cardiology
BMJ,
December 11, 2004;
329(7479):
1386 - 1389.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Krumholz
The year in health care delivery and outcomes research
J. Am. Coll. Cardiol.,
September 1, 2004;
44(5):
1130 - 1136.
[Full Text]
[PDF]
|
|
|
|
